The national conversation around prescription drug pricing is back in full force. From the recent Most Favored Nation (MFN) executive order to President Trump’s letter urging pharmaceutical companies to offer direct-to-consumer (DTC) pricing for brand medications, it’s clear we’re at a pivotal moment for American healthcare. It’s a moment that demands more than just rhetoric; it demands innovation, pragmatism, and above all, deep collaboration across the industry.
For too long, the cost of prescriptions has been shrouded in mystery. Patients show up at the pharmacy counter only to be blindsided by costs they never saw coming, confused by copays, high deductibles, and opaque coverage rules. It’s no wonder almost a billion prescriptions are left at the pharmacy counter each year.
